Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multi-center, Open-label, Single-Arm Study Using Gemcitabine and Panitumumab in the First-line Treatment of Subjects With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas

NCT00613730 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00613730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00613730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multi-center, Open-label, Single-Arm Study Using Gemcitabine and Panitumumab in the First-line Treatment of Subjects With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2007
Completion date
April 30, 2009
Enrollment
3 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of pancreas, cancer of the pancreas, pancreas cancer, pancreatic cancer